ClinicalTrials.gg
TerminatedNCT05556265Updated May 31, 2025Results posted

A Study to Evaluate Efficacy and Safety of Deucravacitinib in Participants With Alopecia Areata

A Phase 2 interventional study of Deucravacitinib and Placebo in Alopecia Areata, sponsored by Bristol-Myers Squibb. Terminated at 28 sites in 6 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-05-31.

Sponsored by Bristol-Myers Squibb · Phase 2, Interventional, and Treatment

Why this study was terminated
Business objectives have changed

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
94
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 98 studies in Alopecia Areata with a site in United States — 21 open to participants now, 32 under way, 8 of them phase 3. Alopecia Areata · United States.

Enrollment
21st of 84
94 · median 46
Started
2022
with 6 others
Phase 2
42 of 98
8 open now
Registered
67th of 98
by date

Among the 98 studies in Alopecia Areata with a site in United States, this one is the 21st largest by enrollment of the 84 interventional ones that give a count, is one of 7 that started in 2022, is one of 42 in phase 2, and was the 67th registered.

Alopecia Areata

220 studies on the registry are indexed under Alopecia Areata; 61 are open to participants now.

Browse Alopecia Areata studies →

Open to participants now

21 of the 98 studies in Alopecia Areata with a site in United States are open now. Recruiting first, the newest first:

16 more — sign in →

All 21 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 41 Alopecia Areata studies recruiting now, 16 (39%) set no upper age limit and 21 (51%) stop at 75 or younger; 20 take children under 18; 5 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 98 studies in Alopecia Areata with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy of deucravacitinib versus placebo at Week 24 and safety and tolerability of deucravacitinib versus placebo in adults with alopecia areata.

03

Conditions studied

  • Alopecia Areata

Browse trials for

Keywords

  • Deucravacitinib
  • IM011134
  • BMS-986165
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Documented clinical diagnosis of alopecia areata (AA) for at least 6 months.
  • Current episode of scalp hair loss (at screening) must meet the following criteria: duration at least 6 months; duration of current hair loss episode of AA affecting ≥ 50% of the scalp not exceeding 8 years; scalp hair loss has been stable (no significant spontaneous regrowth [> 10%] over the last 6 months)
  • SALT score ≥ 50 at Screening and Day 1. Participant with complete scalp hair loss (SALT score of 100) with or without body hair involvement can be included.

Exclusion criteria

Exclusion Criteria:

  • Participant with diffuse-type AA or other forms of hair loss, including traction alopecia, lichen planopilaris, central centrifugal cicatricial alopecia, frontal fibrosing alopecia, etc.
  • Other active skin diseases affecting the scalp that in the opinion of the investigator may interfere with accurate assessment of SALT score.
  • Extensive tattooing of the scalp that, in the opinion of the investigator, may interfere with the accurate assessment of SALT score.

Other protocol-defined inclusion/exclusion criteria apply.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
94 participants (actual)

Study arms

  • Experimental
    Deucravacitinib Dose 1

    Drug: Deucravacitinib · Other: Placebo

  • Experimental
    Deucravacitinib Dose 2

    Drug: Deucravacitinib · Other: Placebo

  • Placebo comparator
    Placebo, followed by Deucravacitinib Dose 1 or Dose 2.

    Drug: Deucravacitinib · Other: Placebo

Interventions

  • Specified dose on specified days

    Also known as: BMS-986165

  • OtherPlacebo

    Placebo was administered.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Severity of Alopecia Tool Score at Week 24 in Placebo-Controlled Treatment Period

    The Severity of Alopecia Tool (SALT) score is a quantitative rating scale for measuring the severity of alopecia areata based on the amount of terminal hair loss in each of the 4 quadrants of the scalp: back region, top region, left and right regions of the scalp. To calculate a SALT score, the degree of scalp hair loss, as a percentage of each scalp region affected, is determined. Each region is multiplied by it's respective weighting factor (percentage surface area of the scalp in that area; back region \[24%\], top region \[40%\], left region \[18%\] and, right region \[18%\]), in order to achieve a subtotal for each region. The SALT score is the sum of the scalp hair loss in each area (sum of the subtotals). The score ranges from 0 to 100, the higher score reflects high severity of alopecia areata.

    Time frame: Baseline (Day 1) and Week 24

  2. Number of Participants With Treatment Emergent Adverse Events in Placebo-Controlled Period

    An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization. Adverse event of interest included herpes zoster, malignancy, opportunistic infection or tuberculosis infection.

    Time frame: From first dose (Day 1) and up to 30 days after last dose for all participants (up to approximately 28 weeks)

  3. Number of Participants With Treatment Emergent Adverse Events in Active Treatment Period

    An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization. Adverse event of interest included Herpes zoster, malignancy, opportunities infection or tuberculosis infection.

    Time frame: From first dose (Day 1) of Week 25 and up to 30 days after last dose for all participants (up to approximately 28 weeks)

  4. Number of Participants With Worst Toxicity Grade Change From Baseline to Grade 3/Grade 4 in Laboratory Test Results as Per Common Terminology Criteria for Adverse Events (CTCAE) v5.0 in Placebo-Controlled Period

    Blood samples were collected for assessment of laboratory test results. All abnormalities were graded as per CTCAE v5.0 on a scale from 1 to 4, with Grade 1 being mild and asymptomatic; Grade 2 is moderate requiring minimal, local or noninvasive intervention; Grade 3 is severe or medically significant but not immediately life-threatening; Grade 4 events are usually severe enough to require hospitalization.

    Time frame: From first dose (Day 1) through Week 24

  5. Number of Participants With Worst Toxicity Grade Change From Baseline to Grade 3/Grade 4 in Laboratory Test Results as Per Common Terminology Criteria for Adverse Events (CTCAE) v5.0 in in Active Treatment Period

    Blood samples were collected for assessment of laboratory test results. All abnormalities are graded as per CTCAE v5.0 on a scale from 1 to 4, with Grade 1 being mild and asymptomatic; Grade 2 is moderate requiring minimal, local or noninvasive intervention; Grade 3 is severe or medically significant but not immediately life-threatening; Grade 4 events are usually severe enough to require hospitalization.

    Time frame: From Week 25 to Week 52

  6. Number of Participants With Marked Electrocardiogram Abnormalities in Placebo-Controlled Period

    A 12-lead ECG was performed after the participant remained supine for at least 5 minutes prior to the ECG. The ECG results read by the principal study investigator or a qualified and delegated designee as per local requirements

    Time frame: First dose (Day 1) to Week 24

  7. Number of Participants With Marked Electrocardiogram Abnormalities in Active Treatment Period

    A 12-lead ECG should be performed after the participant has remained supine for at least 5 minutes prior to the ECG. The ECG results will be read by the principal study investigator or a qualified and delegated designee as per local requirements

    Time frame: Week 25 to Week 52

  8. Number of Participants With Abnormalities in Marked Vital Signs in Placebo-Controlled Period

    Vital signs such as systolic blood pressures (SBP), diastolic blood pressure (DBP) and heart rate were assessed. The evaluation of the marked abnormality criteria is based on participants highest change from baseline in the period. Blood pressure and heart rate were to be measured after the participant has been resting quietly for at least 5 minutes.

    Time frame: First dose (Day 1) to Week 24

  9. Number of Participants With Abnormalities in Marked Vital Signs in Active Treatment Period

    Vital signs such as systolic blood pressures (SBP), diastolic blood pressure (DBP) and heart rate were assessed. The evaluation of the marked abnormality criteria is based on participants highest change from baseline in the period. Blood pressure and heart rate were to be measured after the participant had been resting quietly for at least 5 minutes.

    Time frame: Week 25 to Week 52

  10. Number of Participants With Abnormalities in Targeted Physical Examination Parameters in Placebo-Controlled Period

    Participants were assessed for abnormalities in targeted physical parameters.

    Time frame: First dose (Day 1) to Week 24

  11. Number of Participants With Abnormalities in Targeted Physical Examination Parameters in Active Treatment Parameters

    Participants were assessed for abnormalities in targeted physical parameters.

    Time frame: Week 25 to Week 52

Secondary outcomes

  1. Percentage of Participants Achieving a ≥ 50% Reduction in Severity of Alopecia Tool (SALT) Score (SALT50 Response) From Baseline at Week 24

    The Severity of Alopecia Tool (SALT) score is a quantitative rating scale for measuring the severity of alopecia areata based on the amount of terminal hair loss in each of the 4 quadrants of the scalp; back region, top region, left and right regions of the scalp. To calculate a SALT score, the degree of scalp hair loss, as a percentage of each scalp region affected, is determined. Each region is multiplied by its respective weighting factor (percentage surface area of the scalp in that area; Back region \[24%\], Left Region \[18%\], Right Region \[18%\], Top Region \[40%\]), in order to achieve a subtotal for each region. The SALT score is the sum of the scalp hair loss in each area (sum of the subtotals). The score ranges from 0 to 100, the higher score reflects high severity of alopecia areata. SALT50 response indicates at least a 50% improvement from baseline in the SALT score at a particular time point, indicating 50% hair regrowth.

    Time frame: Baseline (Day 1) and Week 24

  2. Percentage of Participants Achieving a Severity of Alopecia Tool (SALT) Score ≤20 at Week 24

    The Severity of Alopecia Tool (SALT) score is a quantitative rating scale for measuring the severity of alopecia areata based on the amount of terminal hair loss in each of the 4 quadrants of the scalp; back region, top region, left and right regions of the scalp. To calculate a SALT score, the degree of scalp hair loss, as a percentage of each scalp region affected, is determined. Each region is multiplied by its respective weighting factor (percentage surface area of the scalp in that area; Back region \[24%\], Left Region \[18%\], Right Region \[18%\], Top Region \[40%\]), in order to achieve a subtotal for each region. The SALT score is the sum of the scalp hair loss in each area (sum of the subtotals). The score ranges from 0 to 100, the higher score reflects high severity of alopecia areata. percentage of participants achieving an absolute SALT score ≤ 20, indicates ≤ 20% scalp hair loss.

    Time frame: Baseline (Day 1) and Week 24

  3. Percentage of Participants Achieving an Alopecia Areata Investigator Global Assessment (AA-IGA) Score of 0 or 1 at Week 24 With at Least a 2-Point Change From Baseline

    The AA-IGA utilizes a 5-points scale, in which the investigator assesses scalp hair loss based on the SALT assessment. The AA-IGA measures alopecia areata severity at a single point in time(without taking into account the baseline disease condition).The participant's scalp hair loss, as it look at the time of evaluation is scored as none (0) (0% scalp hair loss), limited (1) (1%-20% scalp hair loss), moderate (2) (21%-49% scalp hair loss), severe (3) (50%-94% scalp hair loss), or very severe (4)(95%-100 % scalp hair loss).

    Time frame: Baseline (Day 1) and week 24

07

Results

Posted Feb 28, 2025

Participant flow

Study was terminated due to change in business objectives.

Placebo-Controlled (Day 1 to Week 24)
Participant flow — Placebo-Controlled (Day 1 to Week 24)
MilestoneDeucravacitinib 6 mg QDDeucravacitinib 6 mg BIDPlaceboActive Treatment Period: Placebo Followed by Deucravacitinib 6 mg QDActive-Treatment Period: Placebo Followed by Deucravacitinib 6 mg BID
Started32313100
Completed32263100
Not completed05000
Withdrew: Withdrawal by subject01000
Withdrew: Participant request to discontinue study treatment02000
Withdrew: Adverse event02000
Active Treatment (Week 25 to Week 52)
Participant flow — Active Treatment (Week 25 to Week 52)
MilestoneDeucravacitinib 6 mg QDDeucravacitinib 6 mg BIDPlaceboActive Treatment Period: Placebo Followed by Deucravacitinib 6 mg QDActive-Treatment Period: Placebo Followed by Deucravacitinib 6 mg BID
Started322601615
Completed85053
Not completed242101112
Withdrew: Withdrawal by subject22031
Withdrew: Participant request to discontinue study treatment13001
Withdrew: Study terminated by sponsor1912069
Withdrew: Lost to follow-up02001
Withdrew: Lack of efficacy11010
Withdrew: Adverse event11010

Outcome measures

PrimaryChange From Baseline in Severity of Alopecia Tool Score at Week 24 in Placebo-Controlled Treatment Period

The Severity of Alopecia Tool (SALT) score is a quantitative rating scale for measuring the severity of alopecia areata based on the amount of terminal hair loss in each of the 4 quadrants of the scalp: back region, top region, left and right regions of the scalp. To calculate a SALT score, the degree of scalp hair loss, as a percentage of each scalp region affected, is determined. Each region is multiplied by it's respective weighting factor (percentage surface area of the scalp in that area; back region \[24%\], top region \[40%\], left region \[18%\] and, right region \[18%\]), in order to achieve a subtotal for each region. The SALT score is the sum of the scalp hair loss in each area (sum of the subtotals). The score ranges from 0 to 100, the higher score reflects high severity of alopecia areata.

Time frame:
Baseline (Day 1) and Week 24
Reported as:
Mean · Score on a Scale
Change From Baseline in Severity of Alopecia Tool Score at Week 24 in Placebo-Controlled Treatment Period
Score on a ScalePlacebo-Controlled: Deucravacitinib 6 mg QDPlacebo-Controlled: Deucravacitinib 6 mg BIDPlacebo
Change From Baseline in Severity of Alopecia Tool Score at Week 24 in Placebo-Controlled Treatment Period-5.809 ± 13.38921.027 ± 14.7258-7.302 ± 17.8732
PrimaryNumber of Participants With Treatment Emergent Adverse Events in Placebo-Controlled Period

An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization. Adverse event of interest included herpes zoster, malignancy, opportunistic infection or tuberculosis infection.

Time frame:
From first dose (Day 1) and up to 30 days after last dose for all participants (up to approximately 28 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events in Placebo-Controlled Period
ParticipantsPlacebo-Controlled: Deucravacitinib 6 mg QDPlacebo-Controlled: Deucravacitinib 6 mg BIDPlacebo
Treatment Emergent Adverse Events252820
Serious Treatment Emergent Adverse Events110
Treatment Emergent Adverse Events Leading to Discontinuation of Study130
TEAE of Interest-Herpes Zoster100
TEAE of Interest-Malignancy-Bowen's Disease)010
TEAE of Interest-Malignancy-Nodular lymphocyte predominant Hodgkin Lymphoma010
TEAE of Interest - Opportunistic Infections000
TEAE of Interest - Tuberculosis Infection000
PrimaryNumber of Participants With Treatment Emergent Adverse Events in Active Treatment Period

An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any dose results in death, is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization. Adverse event of interest included Herpes zoster, malignancy, opportunities infection or tuberculosis infection.

Time frame:
From first dose (Day 1) of Week 25 and up to 30 days after last dose for all participants (up to approximately 28 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events in Active Treatment Period
ParticipantsActive Treatment Period: Deucravacitinib 6 mg QDActive Treatment Period: Deucravacitinib 6 mg BIDActive Treatment Period: Placebo Followed by Deucravacitinib 6 mg QDActive Treatment Period: Placebo Followed by Deucravacitinib 6 mg BID
Treatment Emergent Adverse Events21171314
Serious Treatment Emergent Adverse Events0100
Treatment Emergent Adverse Events Leading to Discontinuation of Study1010
TEAE of Interest-Herpes Zoster0000
TEAE of Interest-Malignancy-Bowen's Disease0000
TEAE of Interest-Malignancy-Nodular lymphocyte predominant Hodgkin Lymphoma0000
TEAE of Interest - Opportunistic Infections0000
TEAE of Interest - Tuberculosis Infection0000
PrimaryNumber of Participants With Worst Toxicity Grade Change From Baseline to Grade 3/Grade 4 in Laboratory Test Results as Per Common Terminology Criteria for Adverse Events (CTCAE) v5.0 in Placebo-Controlled Period

Blood samples were collected for assessment of laboratory test results. All abnormalities were graded as per CTCAE v5.0 on a scale from 1 to 4, with Grade 1 being mild and asymptomatic; Grade 2 is moderate requiring minimal, local or noninvasive intervention; Grade 3 is severe or medically significant but not immediately life-threatening; Grade 4 events are usually severe enough to require hospitalization.

Time frame:
From first dose (Day 1) through Week 24
Reported as:
Count of participants · Participants
Number of Participants With Worst Toxicity Grade Change From Baseline to Grade 3/Grade 4 in Laboratory Test Results as Per Common Terminology Criteria for Adverse Events (CTCAE) v5.0 in Placebo-Controlled Period
ParticipantsPlacebo-Controlled: Deucravacitinib 6 mg QDPlacebo-Controlled: Deucravacitinib 6 mg BIDPlacebo
HEMOGLOBIN, LOW000
PLATELET COUNT, LOW000
LEUKOCYTES, LOW000
ALANINE AMINOTRANSFERASE (ALT), HIGH000
ALKALINE PHOSPHATASE (ALP), HIGH000
ASPARTATE AMINOTRANSFERASE (AST), HIGH000
BILIRUBIN, TOTAL, HIGH000
CREATININE, ENZYMATIC, HIGH000
ALBUMIN, LOW000
CALCIUM, LOW000
CALCIUM, HIGH000
CHOLESTEROL, TOTAL (TC), HIGH000
CREATINE KINASE (CK), HIGH012
GLUCOSE, LOW000
POTASSIUM, LOW000
POTASSIUM, HIGH000
SODIUM, LOW000
SODIUM, HIGH000
TRIGLYCERIDES, HIGH000
GLUCOSE FASTING, LOW000
PrimaryNumber of Participants With Worst Toxicity Grade Change From Baseline to Grade 3/Grade 4 in Laboratory Test Results as Per Common Terminology Criteria for Adverse Events (CTCAE) v5.0 in in Active Treatment Period

Blood samples were collected for assessment of laboratory test results. All abnormalities are graded as per CTCAE v5.0 on a scale from 1 to 4, with Grade 1 being mild and asymptomatic; Grade 2 is moderate requiring minimal, local or noninvasive intervention; Grade 3 is severe or medically significant but not immediately life-threatening; Grade 4 events are usually severe enough to require hospitalization.

Time frame:
From Week 25 to Week 52
Reported as:
Count of participants · Participants
Number of Participants With Worst Toxicity Grade Change From Baseline to Grade 3/Grade 4 in Laboratory Test Results as Per Common Terminology Criteria for Adverse Events (CTCAE) v5.0 in in Active Treatment Period
ParticipantsActive Treatment Period: Deucravacitinib 6 mg QDActive Treatment Period: Deucravacitinib 6 mg BIDActive Treatment Period: Placebo Followed by Deucravacitinib 6 mg QDActive Treatment Period: Placebo Followed by Deucravacitinib 6 mg BID
HEMOGLOBIN, LOW0000
PLATELET COUNT, LOW0000
LEUKOCYTES, LOW0000
ALANINE AMINOTRANSFERASE (ALT), HIGH0000
ALKALINE PHOSPHATASE (ALP), HIGH0000
ASPARTATE AMINOTRANSFERASE (AST), HIGH0000
BILIRUBIN, TOTAL, HIGH0000
CREATININE, ENZYMATIC, HIGH0000
ALBUMIN, LOW0000
CALCIUM, LOW0000
CALCIUM, HIGH0000
CHOLESTEROL, TOTAL (TC), HIGH0000
CREATINE KINASE (CK), HIGH0000
GLUCOSE, LOW0000
POTASSIUM, LOW0000
POTASSIUM, HIGH0000
SODIUM, LOW0000
SODIUM, HIGH0000
TRIGLYCERIDES, HIGH0000
GLUCOSE FASTING, LOW0000
PrimaryNumber of Participants With Marked Electrocardiogram Abnormalities in Placebo-Controlled Period

A 12-lead ECG was performed after the participant remained supine for at least 5 minutes prior to the ECG. The ECG results read by the principal study investigator or a qualified and delegated designee as per local requirements

Time frame:
First dose (Day 1) to Week 24
Reported as:
Count of participants · Participants
Number of Participants With Marked Electrocardiogram Abnormalities in Placebo-Controlled Period
ParticipantsPlacebo-Controlled: Deucravacitinib 6 mg QDPlacebo-Controlled: Deucravacitinib 6 mg BIDPlacebo
QTCF 450 -< 480 MILLISECONDS (MSEC)021
QTCF 480 -< 500 MSEC000
QTCF >= 500 MSEC000
QTCF 30 < CHANGE FROM BASELINE <= 60 MSEC010
QTCF CHANGE FROM BASELINE > 60 MSEC000
PR INTERVAL >= 200 MSEC201
QRS INTERVAL >= 120 MSEC001
PrimaryNumber of Participants With Marked Electrocardiogram Abnormalities in Active Treatment Period

A 12-lead ECG should be performed after the participant has remained supine for at least 5 minutes prior to the ECG. The ECG results will be read by the principal study investigator or a qualified and delegated designee as per local requirements

Time frame:
Week 25 to Week 52
Reported as:
Count of participants · Participants
Number of Participants With Marked Electrocardiogram Abnormalities in Active Treatment Period
ParticipantsActive Treatment Period: Deucravacitinib 6 mg QDActive Treatment Period: Deucravacitinib 6 mg BIDActive Treatment Period: Placebo Followed by Deucravacitinib 6 mg QDActive Treatment Period: Placebo Followed by Deucravacitinib 6 mg BID
QTCF 450 -< 480 MILLISECONDS (MSEC)0000
QTCF 480 -< 500 MSEC0000
QTCF >= 500 MSEC0000
QTCF 30 < CHANGE FROM BASELINE <= 60 MSEC1111
QTCF CHANGE FROM BASELINE > 60 MSEC0000
PR INTERVAL >= 200 MSEC1011
QRS INTERVAL >= 120 MSEC1010
PrimaryNumber of Participants With Abnormalities in Marked Vital Signs in Placebo-Controlled Period

Vital signs such as systolic blood pressures (SBP), diastolic blood pressure (DBP) and heart rate were assessed. The evaluation of the marked abnormality criteria is based on participants highest change from baseline in the period. Blood pressure and heart rate were to be measured after the participant has been resting quietly for at least 5 minutes.

Time frame:
First dose (Day 1) to Week 24
Reported as:
Count of participants · Participants
Number of Participants With Abnormalities in Marked Vital Signs in Placebo-Controlled Period
ParticipantsPlacebo-Controlled: Deucravacitinib 6 mg QDPlacebo-Controlled: Deucravacitinib 6 mg BIDPlacebo
HEART RATE > 100 BPM AND CHANGE FROM BASELINE > 30 BPM010
HEART RATE < 55 BPM AND CHANGE FROM BASELINE < -15 BPM100
SBP >140 MM HG AND CHANGE FROM BASELINE > 20 MM HG141
SBP <90 MM HG AND CHANGE FROM BASELINE < -20 MM HG001
DBP >90 MM HG AND CHANGE FROM BASELINE > 10 MM HG301
DBP <55 MM HG AND CHANGE FROM BASELINE < -10 MM HG001
PrimaryNumber of Participants With Abnormalities in Marked Vital Signs in Active Treatment Period

Vital signs such as systolic blood pressures (SBP), diastolic blood pressure (DBP) and heart rate were assessed. The evaluation of the marked abnormality criteria is based on participants highest change from baseline in the period. Blood pressure and heart rate were to be measured after the participant had been resting quietly for at least 5 minutes.

Time frame:
Week 25 to Week 52
Reported as:
Count of participants · Participants
Number of Participants With Abnormalities in Marked Vital Signs in Active Treatment Period
ParticipantsActive Treatment Period: Deucravacitinib 6 mg QDActive Treatment Period: Deucravacitinib 6 mg BIDActive Treatment Period: Placebo Followed by Deucravacitinib 6 mg QDActive Treatment Period: Placebo Followed by Deucravacitinib 6 mg BID
HEART RATE > 100 BPM AND CHANGE FROM BASELINE > 30 BPM0001
HEART RATE < 55 BPM AND CHANGE FROM BASELINE < -15 BPM1100
SBP >140 MM HG AND CHANGE FROM BASELINE > 20 MM HG1101
SBP <90 MM HG AND CHANGE FROM BASELINE < -20 MM HG0000
DBP >90 MM HG AND CHANGE FROM BASELINE > 10 MM HG0103
DBP <55 MM HG AND CHANGE FROM BASELINE < -10 MM HG1010
SecondaryPercentage of Participants Achieving a ≥ 50% Reduction in Severity of Alopecia Tool (SALT) Score (SALT50 Response) From Baseline at Week 24

The Severity of Alopecia Tool (SALT) score is a quantitative rating scale for measuring the severity of alopecia areata based on the amount of terminal hair loss in each of the 4 quadrants of the scalp; back region, top region, left and right regions of the scalp. To calculate a SALT score, the degree of scalp hair loss, as a percentage of each scalp region affected, is determined. Each region is multiplied by its respective weighting factor (percentage surface area of the scalp in that area; Back region \[24%\], Left Region \[18%\], Right Region \[18%\], Top Region \[40%\]), in order to achieve a subtotal for each region. The SALT score is the sum of the scalp hair loss in each area (sum of the subtotals). The score ranges from 0 to 100, the higher score reflects high severity of alopecia areata. SALT50 response indicates at least a 50% improvement from baseline in the SALT score at a particular time point, indicating 50% hair regrowth.

Time frame:
Baseline (Day 1) and Week 24
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving a ≥ 50% Reduction in Severity of Alopecia Tool (SALT) Score (SALT50 Response) From Baseline at Week 24
Percentage of participantsPlacebo-Controlled: Deucravacitinib 6 mg QDPlacebo-Controlled: Deucravacitinib 6 mg BIDPlacebo
Percentage of Participants Achieving a ≥ 50% Reduction in Severity of Alopecia Tool (SALT) Score (SALT50 Response) From Baseline at Week 243.106.5
SecondaryPercentage of Participants Achieving a Severity of Alopecia Tool (SALT) Score ≤20 at Week 24

The Severity of Alopecia Tool (SALT) score is a quantitative rating scale for measuring the severity of alopecia areata based on the amount of terminal hair loss in each of the 4 quadrants of the scalp; back region, top region, left and right regions of the scalp. To calculate a SALT score, the degree of scalp hair loss, as a percentage of each scalp region affected, is determined. Each region is multiplied by its respective weighting factor (percentage surface area of the scalp in that area; Back region \[24%\], Left Region \[18%\], Right Region \[18%\], Top Region \[40%\]), in order to achieve a subtotal for each region. The SALT score is the sum of the scalp hair loss in each area (sum of the subtotals). The score ranges from 0 to 100, the higher score reflects high severity of alopecia areata. percentage of participants achieving an absolute SALT score ≤ 20, indicates ≤ 20% scalp hair loss.

Time frame:
Baseline (Day 1) and Week 24
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving a Severity of Alopecia Tool (SALT) Score ≤20 at Week 24
Percentage of participantsPlacebo-Controlled: Deucravacitinib 6 mg QDPlacebo-Controlled: Deucravacitinib 6 mg BIDPlacebo
Percentage of Participants Achieving a Severity of Alopecia Tool (SALT) Score ≤20 at Week 243.100
SecondaryPercentage of Participants Achieving an Alopecia Areata Investigator Global Assessment (AA-IGA) Score of 0 or 1 at Week 24 With at Least a 2-Point Change From Baseline

The AA-IGA utilizes a 5-points scale, in which the investigator assesses scalp hair loss based on the SALT assessment. The AA-IGA measures alopecia areata severity at a single point in time(without taking into account the baseline disease condition).The participant's scalp hair loss, as it look at the time of evaluation is scored as none (0) (0% scalp hair loss), limited (1) (1%-20% scalp hair loss), moderate (2) (21%-49% scalp hair loss), severe (3) (50%-94% scalp hair loss), or very severe (4)(95%-100 % scalp hair loss).

Time frame:
Baseline (Day 1) and week 24
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving an Alopecia Areata Investigator Global Assessment (AA-IGA) Score of 0 or 1 at Week 24 With at Least a 2-Point Change From Baseline
Percentage of participantsPlacebo-Controlled: Deucravacitinib 6 mg QDPlacebo-Controlled: Deucravacitinib 6 mg BIDPlacebo
Percentage of Participants Achieving an Alopecia Areata Investigator Global Assessment (AA-IGA) Score of 0 or 1 at Week 24 With at Least a 2-Point Change From Baseline3.100
PrimaryNumber of Participants With Abnormalities in Targeted Physical Examination Parameters in Placebo-Controlled Period

Participants were assessed for abnormalities in targeted physical parameters.

Time frame:
First dose (Day 1) to Week 24
Reported as:
Count of participants · Participants
Number of Participants With Abnormalities in Targeted Physical Examination Parameters in Placebo-Controlled Period
ParticipantsPlacebo-Controlled: Deucravacitinib 6 mg QDPlacebo-Controlled: Deucravacitinib 6 mg BIDPlacebo
Abdomen001
Extremities011
General Appearance110
Genitourinary100
Head, Eyes, Ears, Nose, Throat362
Lymph Nodes000
Mouth300
Musculoskeletal110
Neck000
Neurological201
Psychiatric101
Respiratory011
Skin9146
Other110
PrimaryNumber of Participants With Abnormalities in Targeted Physical Examination Parameters in Active Treatment Parameters

Participants were assessed for abnormalities in targeted physical parameters.

Time frame:
Week 25 to Week 52
Reported as:
Count of participants · Participants
Number of Participants With Abnormalities in Targeted Physical Examination Parameters in Active Treatment Parameters
ParticipantsActive Treatment Period: Deucravacitinib 6 mg QDActive Treatment Period: Deucravacitinib 6 mg BIDActive Treatment Period: Placebo Followed by Deucravacitinib 6 mg QDActive Treatment Period: Placebo Followed bDeucravacitinib 6 mg BID
Abdomen0300
Extremities0100
General Appearance0000
Genitourinary1100
Head, Eyes, Ears, Nose, Throat0522
Lymph Nodes0100
Mouth2112
Musculoskeletal1210
Neck0100
Neurological0000
Other2204
Psychiatric0001
Respiratory1302
Skin8658

Adverse events

Collected over All cause mortality was collected from Week 0 to Week 52. Serious AEs were collected from informed consent form signing (Week -4) and up to 30 days after last dose for all participants (up to approximately 32 weeks and 28 weeks in Placebo-controlled and Active Treatment Period respectively). Non Serious AEs were collected from first dose (Day 1) and up to 30 days after last dose (up to approximately 28 weeks for each Placebo-controlled and Active Treatment Period).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo-Controlled: Deucravacitinib 6 mg QD0/32 (0%)1/32 (3.1%)24/32 (75%)
Placebo-Controlled: Deucravacitinib 6 mg BID0/31 (0%)1/31 (3.2%)26/31 (83.9%)
Placebo0/31 (0%)0/31 (0%)16/31 (51.6%)
Active-Treatment Period: Deucravacitinib 6 mg QD0/32 (0%)0/32 (0%)15/32 (46.9%)
Active-Treatment Period: Deucravacitinib 6 mg BID0/26 (0%)1/26 (3.8%)14/26 (53.8%)
Active-Treatment Period: Placebo Followed by Deucravacitinib 6 mg QD0/16 (0%)0/16 (0%)13/16 (81.3%)
Active-Treatment Period: Placebo Followed by Deucravacitinib 6 mg BID0/15 (0%)0/15 (0%)14/15 (93.3%)
Most frequent serious events
Most frequent serious events
EventPlacebo-Controlled: Deucravacitinib 6 mg QDPlacebo-Controlled: Deucravacitinib 6 mg BIDPlaceboActive-Treatment Period: Deucravacitinib 6 mg QDActive-Treatment Period: Deucravacitinib 6 mg BIDActive-Treatment Period: Placebo Followed by Deucravacitinib 6 mg QDActive-Treatment Period: Placebo Followed by Deucravacitinib 6 mg BID
Ligament sprainInjury, poisoning and procedural complications0/320/310/310/321/260/160/15
Nodular lymphocyte predominant Hodgkin LymphomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/321/310/310/320/260/160/15
Viral upper respiratory tract infectionInfections and infestations1/320/310/310/320/260/160/15
Most frequent other events
Showing 10 of 44
Most frequent other events
EventPlacebo-Controlled: Deucravacitinib 6 mg QDPlacebo-Controlled: Deucravacitinib 6 mg BIDPlaceboActive-Treatment Period: Deucravacitinib 6 mg QDActive-Treatment Period: Deucravacitinib 6 mg BIDActive-Treatment Period: Placebo Followed by Deucravacitinib 6 mg QDActive-Treatment Period: Placebo Followed by Deucravacitinib 6 mg BID
Upper respiratory tract infectionInfections and infestations2/324/314/314/325/264/164/15
AcneSkin and subcutaneous tissue disorders5/324/313/310/320/263/164/15
NasopharyngitisInfections and infestations5/328/310/312/326/262/161/15
FolliculitisInfections and infestations5/326/311/310/320/260/161/15
Aphthous ulcerGastrointestinal disorders3/324/311/310/322/261/162/15
Food poisoningGastrointestinal disorders0/321/310/310/320/260/162/15
COVID-19Infections and infestations3/321/310/311/321/260/162/15
DiarrhoeaGastrointestinal disorders1/324/310/310/320/260/160/15
EczemaSkin and subcutaneous tissue disorders1/321/310/310/320/262/161/15
Urinary tract infectionInfections and infestations1/323/310/312/321/260/160/15

Baseline characteristics

Age, Continuous
Age, Continuous(years)Deucravacitinib 6 mg QDDeucravacitinib 6 mg BIDPlaceboTotal
Mean36.1 ± 13.3743.4 ± 13.8138.9 ± 14.4039.4 ± 14.04
Sex: Female, Male
Sex: Female, Male(Participants)Deucravacitinib 6 mg QDDeucravacitinib 6 mg BIDPlaceboTotal
Female22222064
Male1091130
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Deucravacitinib 6 mg QDDeucravacitinib 6 mg BIDPlaceboTotal
Hispanic or Latino1304
Not Hispanic or Latino31283190
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Deucravacitinib 6 mg QDDeucravacitinib 6 mg BIDPlaceboTotal
American Indian or Alaska Native0000
Asian861024
Native Hawaiian or Other Pacific Islander0000
Black or African American1427
White22201961
More than one race0000
Unknown or Not Reported1102
08

Study locations

28 sites
  • Local Institution - 0016
    Santa Monica, California 90404-2120, United States
  • Local Institution - 0036
    New Haven, Connecticut 06510, United States
  • Local Institution - 0018
    Tampa, Florida 33624-2038, United States
  • Local Institution - 0023
    Clinton Township, Michigan 48038-1137, United States
  • Local Institution - 0024
    New York, New York 10029-6501, United States
  • Local Institution - 0019
    Chapel Hill, North Carolina 27516-4061, United States
  • Local Institution - 0011
    Portland, Oregon 97201-5134, United States
  • Local Institution - 0032
    Pittsburgh, Pennsylvania 15213-3403, United States
  • Local Institution - 0012
    Austin, Texas 78759, United States
  • Local Institution - 0013
    Houston, Texas 77004-8098, United States
  • Local Institution - 0014
    San Antonio, Texas 78213-2250, United States
  • Local Institution - 0017
    South Jordan, Utah 84095, United States
  • Local Institution - 0003
    Kogarah, New South Wales 2217, Australia
  • Local Institution - 0005
    Carlton, Victoria 3053, Australia
  • Local Institution - 0015
    Winnipeg, Manitoba R3M 3Z4, Canada
  • Local Institution - 0021
    Markham, Ontario L3P 1X2, Canada
  • Local Institution - 0009
    Peterborough, Ontario K9J 5K2, Canada
  • Local Institution - 0010
    Richmond Hill, Ontario L4C 9M7, Canada
  • Local Institution - 0034
    Montreal, Quebec H2X 2V1, Canada
  • Local Institution - 0027
    Québec, Quebec G1V 4X7, Canada
  • Local Institution - 0033
    Nice, 06200, France
  • Local Institution - 0020
    Paris, 75010, France
  • Local Institution - 0031
    Hamamatsu, 431-3192, Japan
  • Local Institution - 0028
    Kōtoku, 136-0075, Japan
  • Local Institution - 0030
    Mitaka-Shi, 181-8611, Japan
  • Local Institution - 0029
    Shinjuku-Ku, 160-0023, Japan
  • Local Institution - 0026
    Wroclaw, Lower Silesian Voivodeship 50-566, Poland
  • Local Institution - 0025
    Warsaw, 02-962, Poland
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myers Squibb's data sharing policy and process can be found at: https://www.bms.com/researchers-and-partners/clinical-trials-and-research/disclosurecommitment.html

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See plan description

Access criteria: See plan description

Data sharing details ↗ · www.bms.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2022 to primary completion in Jan 2024, 13 months.

Results were first posted in Feb 2025, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2022
First posted
Sep 27, 2022
StartActual
Nov 8, 2022
Primary completionActual
Jan 6, 2024
CompletionActual
May 16, 2024
Results first posted
Feb 28, 2025
Last update
May 31, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 31, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05556265
Responsible party
Sponsor
First posted
Sep 27, 2022
Start date
Nov 8, 2022
Primary completion
Jan 6, 2024
Completion
May 16, 2024
Results posted
Feb 28, 2025
Last update
May 31, 2025

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Deucravacitinib

Start the discussion